This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Apr 2012

NICE Rejects Halaven for Breast Cancer Treatment

UK's National Insitiute for Clinical Excellence has rejected Eisai's Halaven for the treatment of advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens.

The National Insitiute for Clinical Excellence in the UK has rejected Eisai's Halaven (eribulin) for the treatment of advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens.

 

The manufacturer provided additional analyses following the consultation period for the subgroup of people previously treated with capecitabine, an orally-administered chemotherapeutic developed by Roche.

 

Halaven was found to potentially extend life by 2.7 months compared with a treatment of physician's choice, but NICE concluded the drug did not fulfil all the end-of-life criteria.

 

The most common adverse effects of the treatment are reported to be fati

Related News